{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'subjects), and nasopharyngitis (12 [3.1%] subjects). The majority of TEAEs were mild or', 'moderate in intensity. The incidence of treatment-related TEAEs with the GSP 301 NS', 'treatment group was generally low and was comparable to placebo treatment groups (7.1% in', 'GSP 301 placebo NS pH 3.7, 9.9% in GSP 301 placebo NS pH 7.0, and 11.2% in GSP 301 NS).', 'The frequency of SAEs with GSP 301 NS treatment group was low and comparable to placebo', 'treatment groups. Eleven subjects experienced SAEs; none of the SAEs were considered by the', 'Investigator to be related to study drug. No deaths occurred during the study. In addition, the', 'frequency of withdrawals with GSP 301 NS treatment group was also low and comparable to', 'placebo treatment groups.', 'Treatment with GSP 301 NS compared with GSP 301 placebo NS pH 3.7 showed statistically', 'significant and clinically meaningful, as well as sustained improvement in nasal symptoms in', 'PAR subjects with no evidence of tachyphylaxis. Specifically, the following were observed', 'when GSP 301 NS was compared with GSP placebo NS pH 3.7 on the efficacy endpoints:', 'Clinically meaningful and statistically significant (p<0.01) improvements in the', 'change from baseline in average AM rTNSS and average AM iTNSS over the 6, 30,', 'and 52 weeks treatment period using repeated measures analyses.', 'Statistically significant improvements in all 4 AM reflective and AM instantaneous', 'individual nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing)', 'over the first 6, 30, and 52 weeks treatment duration (p<0.05).', 'Clinically meaningful improvements in efficacy endpoints (rTNSS and iTNSS) over', 'first 6 weeks of treatment and the efficacy was sustained over the 52 weeks treatment.', 'Statistically significant improvements were also observed on changes from baseline', 'in Rhinoconjunctivitis Quality of Life Questionnaire RQLQ (Standardized activities)', 'at 6 and 30 weeks treatment.', 'Overall, based on the results from the clinical studies conducted as part of the clinical', 'development of GSP 301 NS, the', 'formulation of the GSP 301 NS', 'sprays/nostril', 'of', 'olopatadine hydrochloride g and mometasone furoate g) was found to be safe and', 'effective for the treatment symptoms of SAR in adults and adolescent subjects (aged > 12 years).', '4.5.', 'Benefit-Risk Assessment', 'Olopatadine HCL NS (PATANASE NS; 665 g olopatadine hydrochloride) is approved for the', 'relief of the symptoms of SAR in adults and children aged 6 years and older in the US (12 years', 'of age and older as 2 sprays per nostril twice daily [BID]) and in children 6-11 years of age as', '1', 'spray per nostril BID). The most common (>1%) adverse reactions to olopatadine HCI', 'included bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and', 'urinary tract infection (PATANASE USPI, 2012).', 'Mometasone furoate NS (NASONEX NS; 50 g per spray) has been approved for the treatment', 'of nasal symptoms of AR in subjects 12 years and older (as 2 sprays in each nostril once daily', '[QD], 200 g total daily dose) and in subjects >2 to 11 years of age (as 1 spray per nostril QD;', '100 g total daily dose). Other approved indications include treatment of nasal congestion', 'associated with SAR in subjects >2 years of age, prophylaxis of SAR in subjects >12 years of', 'age, and treatment of nasal polyps in subjects >18 years of age (NASONEX USPI, 2013). The', 'Glenmark', 'CONFIDENTIAL', 'Page 24 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'most common adverse reactions (5%) included headache, viral infection, pharyngitis, epistaxis,', 'cough, sinusitis, upper respiratory infection, dysmenorrhea, and musculoskeletal pain', '(NASONEX USPI, 2013).', 'GSP 301 NS', 'is being considered for evaluation in this pediatric efficacy and safety study in', 'subjects aged >6 to <12 years with SAR. The Sponsor is proposing to match the approved', 'pediatric daily doses for the individual monotherapy products and evaluate', 'of the adult and', 'adolescent daily dosage', 'spray per nostril,', '- olopatadine hydrochloridel', 'g and', 'mometasone furoate g) resulting in a total daily dose of olopatadine hydrochloride', 'g', 'and mometasone furoate', 'g. This proposed pediatric dosage will provide the equivalent', 'total daily dose of the individual monotherapy products as currently approved in the', 'commercially available products, PATANASE NS and NASONEX NS.', 'No nasal irritancy is expected when GSP 301 NS is administered based on evidence from the', 'approved/marketed monotherapy formulations and the fact that the excipients in GSP 301 NS are', 'all generally regarded as safe-approved by the intranasal route.', 'The efficacy and safety of another similar FDC product (DYMISTA - FDC of an antihistamine', 'azelastine HCL and an intranasal corticosteroid fluticasone propionate) in pediatric subjects has', 'been previously reported without any safety concerns. The efficacy and safety of DYMISTA', 'was evaluated in a randomized, multicenter, double-blind, placebo-controlled study in 304', 'children aged 6 to 11 years with SAR. Subjects were randomized 1:1 to receive either one spray', 'per nostril BID of DYMISTA or placebo for 14 days. The primary efficacy endpoint was the', 'mean change from baseline in combined AM+PM rTNSS over 2 weeks. DYMISTA was not', 'statistically significantly different from placebo (p=0.099), but the results were numerically', 'supportive (DYMISTA USPI, 2015). No clinically meaningful difference in the incidence of', 'AEs or in other safety assessments compared with placebo were reported in this study.', 'Another pediatric study evaluated the efficacy and safety of DYMISTA vs fluticasone propionate', '(both 1 spray/nostril BID), in subjects aged > 6 to <12 years [DYMISTA: n = 264; fluticasone', 'propionate: n = 89) with AR in an open-label 3 month study. Over the 3-month period,', 'DYMISTA-treated children experienced significantly greater symptom relief than fluticasone', 'propionate-treated children (treatment difference: -0.14; 95% CI: -0.28, -0.01; P = 0.04). Based', 'on the results, this study concluded that DYMISTA provided significantly greater, more rapid', 'and clinically relevant symptom relief than fluticasone propionate in children with AR', '(Berger et al, 2016). No clinically meaningful difference in the incidence of AEs or in other', 'safety assessments compared with fluticasone propionate were reported in this study.', 'Therefore, it is anticipated that a FDC of olopatadine HCI and mometasone furoate (GSP 301)', 'NS will provide improved efficacy and that the safety will be comparable to the known safety', 'profiles of each monotherapy in pediatric subject population.', '5.', 'STUDY OBJECTIVES AND PURPOSE', '5.1.', 'Primary Objective', 'To compare the efficacy of GSP 301 NS (administered as spray/', 'nostril', 'with placebo NS', 'over 14 days of study drug in pediatric subjects (aged >6 to <12 years) with SAR.', 'Glenmark', 'CONFIDENTIAL', 'Page 25 of 90']\n\n###\n\n", "completion": "END"}